CIS and Terrebonne General Are First in Louisiana to Use the AngioSafe Santreva™-ATK Endovascular Revascularization Catheter
JANUARY 8, 2026 –HOUMA, LA – Cardiovascular Institute of the South (CIS) and Terrebonne General Health System (Terrebonne General) are the first in Louisiana to use the AngioSafe Santreva™-ATK Endovascular Revascularization Catheter to help restore blood flow in patients with peripheral artery disease (PAD). CIS interventional cardiologist and vascular specialist, Dr. Matthew Finn performed this procedure on December 22 at Terrebonne General Health System.
Developed by AngioSafe, the Santreva-ATK is the world’s first wire-free catheter designed to safely cross blocked or very narrow arteries in the upper legs and prepare them for treatment in a single step, using advanced technology to make the procedure more efficient – even in complex cases.
“The AngioSafe Santreva-ATK is an exciting new device for crossing arteries in the leg with 100% chronic blockages,” said Dr. Finn. “It allows for crossing of a very challenging lesion which would usually require additional access points and a longer procedure time.”
“Our partnership with CIS allows us to introduce leading-edge technology that elevates patient care,” said Phyllis Peoples, Terrebonne General President and CEO. “This achievement reflects our ongoing commitment to advancing services and ensuring our community has access to the highest level of cardiac care.”
PAD occurs when the peripheral arteries, most commonly in the legs, become narrowed and restrict blood flow. If left untreated, PAD increases the risk of heart attack and stroke and may progress to Critical Limb Ischemia (CLI), a severe form of artery blockage that significantly limits blood flow to the limbs and can lead to serious complications.
Learn more about CIS or schedule an appointment near you at www.cardio.com.
About Cardiovascular Institute of the South
Founded by Dr. Craig Walker in 1983, Cardiovascular Institute of the South (CIS) is a world-leader in preventing, detecting and treating cardiovascular and peripheral vascular disease. CIS offers a comprehensive heart and vascular program with expert physicians trained in many specialties, including internal medicine, nuclear cardiology, electrophysiology, lipid management, coronary artery disease, peripheral vascular disease, structural heart and valve disease, venous disease and interventional procedures. CIS has earned international acclaim as a pioneer of research, development and education, as well as an innovator in the treatment of peripheral vascular disease. With a dedicated team of more than 1,075 team members, CIS provides comprehensive cardiovascular care at 23 locations across Louisiana and Mississippi, with 10 telemedicine programs. CIS remains at the forefront of technology, providing the highest-quality, compassionate care. For more information about CIS, call 1-800-425-2565 or visit www.cardio.com.
About Terrebonne General Health System
Terrebonne General Health System is the largest healthcare resource provider in southeast Louisiana that has taken the lead to deliver medical excellence and innovation to the people of Southeast Louisiana. Driven by a "high tech" and "high touch" style of healing that offers an expansive range of services that provide hospital care and preventive care while also providing basic healthcare needs on and offsite. Our highly skilled healthcare team consists of over 1,500 employees, with over 450 medical staff providers that offer 42 various specialties. Our system has been honored with many prestigious awards and accolades for quality, safety, and patient experience on the state, national and international levels. Terrebonne General took the lead to initiate a public/private partnership with Ochsner Health which delivers crucial safety-net services for the region through Chabert Medical Center and is part of an alliance of healthcare-focused entities across the greater Gulf South region. For more information, please visit www.tghealthsystem.com and follow us on Facebook, Twitter, and Instagram.
